Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 377,762
  • Shares Outstanding, K 29,745
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,940 K
  • 60-Month Beta -0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 24.28
Trade CADL with:

Options Overview Details

View History
  • Implied Volatility 162.87% ( +1.98%)
  • Historical Volatility 180.39%
  • IV Percentile 20%
  • IV Rank 41.49%
  • IV High 384.07% on 04/18/24
  • IV Low 6.03% on 04/15/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 858
  • Volume Avg (30-Day) 539
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 8,287
  • Open Int (30-Day) 2,193

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +302,827.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.05 +127.72%
on 04/19/24
14.30 -19.58%
on 05/16/24
+6.06 (+111.40%)
since 04/17/24
3-Month
1.34 +758.21%
on 03/18/24
14.30 -19.58%
on 05/16/24
+9.78 (+568.60%)
since 02/16/24
52-Week
0.66 +1,642.42%
on 11/03/23
14.30 -19.58%
on 05/16/24
+9.94 (+637.18%)
since 05/17/23

Most Recent Stories

More News
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...

ONCY : 1.1100 (-1.77%)
CADL : 11.50 (-9.45%)
ABVC : 1.0700 (+0.94%)
CTMX : 1.89 (-5.50%)
AMGN : 312.47 (-0.71%)
ONC.TO : 1.51 (-2.58%)
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer

USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with...

ONCY : 1.1100 (-1.77%)
ONC.TO : 1.51 (-2.58%)
CADL : 11.50 (-9.45%)
ABVC : 1.0700 (+0.94%)
CTMX : 1.89 (-5.50%)
AMGN : 312.47 (-0.71%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.1100 (-1.77%)
CADL : 11.50 (-9.45%)
AZN : 76.90 (-0.18%)
HALO : 44.71 (-1.50%)
JANX : 47.10 (-0.86%)
ONC.TO : 1.51 (-2.58%)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.1100 (-1.77%)
ONC.TO : 1.51 (-2.58%)
CADL : 11.50 (-9.45%)
AZN : 76.90 (-0.18%)
HALO : 44.71 (-1.50%)
JANX : 47.10 (-0.86%)
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

ONCY : 1.1100 (-1.77%)
ONC.TO : 1.51 (-2.58%)
BLRX : 0.6400 (-0.30%)
IMRX : 1.4700 (-4.55%)
CADL : 11.50 (-9.45%)
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage...

CADL : 11.50 (-9.45%)
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that...

CADL : 11.50 (-9.45%)
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Cash position bolstered through debt financing to support operations into the fourth quarter of 2023...

CADL : 11.50 (-9.45%)
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights

-Cash position remains strong to support operations into the fourth quarter of 2023-...

CADL : 11.50 (-9.45%)
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing...

CADL : 11.50 (-9.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 14.90
2nd Resistance Point 14.04
1st Resistance Point 12.77
Last Price 11.50
1st Support Level 10.64
2nd Support Level 9.78
3rd Support Level 8.51

See More

52-Week High 14.30
Last Price 11.50
Fibonacci 61.8% 9.09
Fibonacci 50% 7.48
Fibonacci 38.2% 5.87
52-Week Low 0.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar